StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report issued on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of EVOK stock opened at $5.50 on Thursday. Evoke Pharma has a 12-month low of $4.32 and a 12-month high of $18.60. The firm has a market capitalization of $47.28 million, a price-to-earnings ratio of -3.01 and a beta of 0.38. The business has a 50 day simple moving average of $6.18 and a 200 day simple moving average of $6.62.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($2.04) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%. The business had revenue of $1.74 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- Best Aerospace Stocks Investing
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- How to Calculate Inflation Rate
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- 3 Stocks to Consider Buying in October
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
